260 related articles for article (PubMed ID: 31479631)
21. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Hippo Pathway for Anti-cancer Therapies.
Gong R; Yu FX
Curr Med Chem; 2015; 22(35):4104-17. PubMed ID: 26429069
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
24. Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors.
Bokhovchuk F; Mesrouze Y; Delaunay C; Martin T; Villard F; Meyerhofer M; Fontana P; Zimmermann C; Erdmann D; Furet P; Scheufler C; Schmelzle T; Chène P
Protein Sci; 2020 Feb; 29(2):509-520. PubMed ID: 31697419
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.
Pobbati AV; Han X; Hung AW; Weiguang S; Huda N; Chen GY; Kang C; Chia CS; Luo X; Hong W; Poulsen A
Structure; 2015 Nov; 23(11):2076-86. PubMed ID: 26592798
[TBL] [Abstract][Full Text] [Related]
26. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
[TBL] [Abstract][Full Text] [Related]
27. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
[TBL] [Abstract][Full Text] [Related]
28. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
29. Direct inhibition of the YAP:TEAD interaction: an unprecedented drug discovery challenge.
Chene P
ChemMedChem; 2024 Jun; ():e202400361. PubMed ID: 38863297
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.
Smith SA; Sessions RB; Shoemark DK; Williams C; Ebrahimighaei R; McNeill MC; Crump MP; McKay TR; Harris G; Newby AC; Bond M
J Med Chem; 2019 Feb; 62(3):1291-1305. PubMed ID: 30640473
[TBL] [Abstract][Full Text] [Related]
31. Blockage of glioma cell survival by truncated TEAD-binding domain of YAP.
Zhao W; Dong QF; Li LW; Yan ZF; Huo JL; Chen XY; Yang X; Li PQ; Fei Z; Zhen HN
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1713-1723. PubMed ID: 33651140
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
[TBL] [Abstract][Full Text] [Related]
34. Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer.
Li L; Li R; Wang Y
Bioorg Chem; 2022 May; 122():105707. PubMed ID: 35247806
[TBL] [Abstract][Full Text] [Related]
35. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
[TBL] [Abstract][Full Text] [Related]
36. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
37. Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motif.
Nagashima S; Maruyama J; Kawano S; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
Cancer Sci; 2016 Jun; 107(6):791-802. PubMed ID: 27009852
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library.
Lauriola A; Uliassi E; Santucci M; Bolognesi ML; Mor M; Scalvini L; Elisi GM; Gozzi G; Tagliazucchi L; Marverti G; Ferrari S; Losi L; D'Arca D; Costi MP
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214125
[TBL] [Abstract][Full Text] [Related]
39. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
40. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
Elife; 2022 Oct; 11():. PubMed ID: 36300789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
